BPC-157 and TB-500 are the two most-referenced tissue-repair peptides, and the most common question is not which one, but whether to use them separately or together. They arrive at repair from different directions: BPC-157 is a gastric-derived pentadecapeptide studied for local cytoprotective and healing signalling, while TB-500 is a fragment of thymosin beta-4, an actin-regulating protein involved in cell migration. Both carry extensive animal-model literatures and neither has completed human trials, so an honest comparison is mostly about mechanism and evidence type, not proven outcomes.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| What it is | Synthetic pentadecapeptide derived from a gastric protective protein | Synthetic fragment of thymosin beta-4 (Tβ4), an actin-binding protein |
| Studied mechanism | Local cytoprotection, angiogenesis and tendon/ligament/GI healing signalling | Actin regulation, cell migration and wound-site recruitment |
| Evidence base | Large preclinical/animal literature; minimal human data | Preclinical wound-healing and cardiac models (as Tβ4); minimal human data |
| Regulatory status | Not an approved medicine anywhere; FDA has flagged insufficient human safety data | Not an approved medicine anywhere |
| Where it is studied | Tendon, ligament, muscle and gut injury models | Soft-tissue repair, flexibility, cardiac models |
| WADA status | Prohibited in competitive sport | Prohibited in competitive sport (TB-500/Tβ4 named) |
| How it is supplied here | Combined BPC-157 + TB-500 pen (single blend) | Combined BPC-157 + TB-500 pen (single blend) |
BPC-157 is studied as a locally acting healing signal: most of its animal literature involves injury models where it is applied near the damage, in tendon, ligament, muscle or gastrointestinal tissue. TB-500 works further upstream. Thymosin beta-4 regulates actin, the structural protein cells use to move, which is why its literature centres on cell migration into wound sites. The mechanistic difference is the entire rationale for pairing them: one hypothesis for recruitment, one for local repair signalling.
Both compounds have consistent, repeated animal-model results, and that is where the confident claims must stop. Neither has completed a controlled human trial programme, neither has an approved dose, and the FDA has specifically flagged BPC-157 as lacking sufficient human safety information. Protocols circulating online are conventions built on animal extrapolation, not clinical standards.
Reported protocols give the two compounds at different amounts and frequencies, which a fixed 1:1 blend cannot reproduce. That is the trade-off of any combined format. What a single pre-loaded blend does offer is consistency: one sealed solution at a printed concentration rather than two vials reconstituted separately. Which matters more depends on whether you need per-compound precision or a stable combined exposure. We supply the pair as one combined pen.
The tendon and ligament animal literature is larger for BPC-157; TB-500 features more in general soft-tissue and cardiac models. Neither has human trial evidence, so "better" can only describe the preclinical record.
Their hypothesised mechanisms are complementary: TB-500 relates to cell migration into damaged tissue, BPC-157 to local repair signalling. The combination hypothesis dominates the literature, which is why combined formats exist.
No. Neither BPC-157 nor TB-500 is an approved medicine in any jurisdiction, and both are prohibited in competitive sport under WADA.
No. We supply one combined BPC-157 and TB-500 pre-loaded pen. If you need separate per-compound amounts, a fixed blend is the wrong format.
This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Where a compound has held a marketing authorisation, approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.
These two are sold together so often that they get treated as interchangeable halves of one thing. They are not; see what BPC-157 and TB-500 are. Their evidence bases differ in kind as well as in quantity, and that difference is the most useful thing this page can give you.
BPC-157 as an Investigational Peptide Therapeutic: translational development barriers. PMC13210877; Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. PMID 40756949; Thymosin beta-4 ophthalmic solution for dry eye: Phase II. PMID 26056426; NCT01387347; NCT00832091
BPC-157: a large preclinical literature, no approved formulation, no validated dosing regimen, no completed Phase II trial. Human exposure limited to safety trials, including a programme in inflammatory bowel disease under the code PL14736.
Thymosin beta-4: registered human trials that were completed: a Phase II in dry eye, a placebo-controlled dose-response study in venous stasis ulcers, and a Phase III programme in neurotrophic keratopathy.
On the face of it TB-500 looks better evidenced. Read the route and that reverses into something more complicated.
Those thymosin beta-4 trials studied topical and ophthalmic administration for eye-surface and wound-healing indications. They are not trials of systemic injection for tendon, ligament or muscle repair.
So TB-500 has better human evidence, for a use nobody buying it here has in mind. That is a genuinely awkward fact and it belongs on a comparison page.
TB-500 as sold is commonly a fragment of thymosin beta-4 rather than the full-length protein used in those trials. Where that is the case, the trial data does not automatically describe the material in circulation: different molecule, different pharmacokinetics, potentially different activity.
Trial results for thymosin beta-4 describe the full-length protein, and they should not be read across to a fragment as though the two were one molecule. The certificate of analysis is the document that ties a named batch to what was tested; see batch and lot matching.
More than eighty per cent of published BPC-157 studies are attributable by author affiliation to a single research group at the University of Zagreb. Independent replication across separate laboratories is the normal precondition for treating preclinical findings as robust.
This cuts both ways: it weakens the efficacy case and it equally weakens any claim that adverse effects have been ruled out.
They are supplied together, in our case as one combined pen, on the rationale that they act on different parts of tissue repair. No published human trial has administered both and measured the result. The rationale is mechanistic; the combination itself is untested.
Related: repair peptides, dosing in the literature, reported adverse events, peptides for recovery.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy